Catalent Pharma Solutions, a Somerset-based provider of technologies and solutions for drugs, biologics and consumer health products, announced Thursday it has completed the second phase of its $5.5 million expansion program at its 450,000-square-foot Kansas City, Missouri facility.
The expansion, Catalent said, will increase the controlled-substance and controlled-temperature storage capabilities for its clinical supply business.
Phase II marks the end of a two-year project that has also expanded the facility’s highly-potent, cytotoxic and cold-storage clinical drug packaging capabilities.
The expansion includes a new Drug Enforced Administration Schedule I and II controlled substance vault, which provides the site with an additional 3,600 square feet of storage, as well as new controlled temperature storage capacity. The company also installed a new sampling room and a new emergency generator.
“Catalent customers have benefitted from our integrated analytical, oral solid manufacturing, and clinical supply services which our Kansas City, (Missouri) campus has offered continuously for over 18 years,” commented Kevin Economos, general manager of clinical supply services at the site. “These latest expansions are critical enablers to our customers’ continued growth, that reinforce our comprehensive global network, and enhance Catalent’s role as a market leader in the clinical supply industry.”
